Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety evaluation of CM-ADSC eye drops in refractory corneal and conjunctival epithelial disorders
jRCTs031260247Recruiting
- Start
- Jun 2026
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of CM-ADSC eye drops in refractory corneal epithelial disorder, conjunctival epithelial disorder and dry eye syndrome (DED). Primary endpoint: Primary: change in eye irritation score at Week 4. Started Jun 2026; status: recruiting.
02
Drugs
CM-ADSC eye drops
03
Conditions
refractory corneal epithelial disorderconjunctival epithelial disorderdry eye syndrome (DED)
Beyond the preview
Go deeper on jRCTs031260247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260247.